BridgeBio Pharma Inc is a pioneering biopharmaceutical company focused on developing innovative medicines for genetic diseases and cancers. With a robust pipeline, it is advancing treatments through clinical trials, including therapies for TTR amyloidosis, achondroplasia, congenital adrenal hyperplasia, autosomal dominant hypocalcemia, and limb-girdle muscular dystrophy. Founded in 2015 and based in Palo Alto, California, BridgeBio collaborates with leading institutions to transform scientific discoveries into breakthrough treatments.
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle’s disappointing earnings after the bell yesterday. The Federal Reserve’s 25-basis-point rate cut, as expected,…
The latest Consumer Price Index (CPI) report has sparked optimism, revealing consumer prices rose 0.2% in July, meaning the index held steady from June at 2.7%. This was milder than anticipated, but…
A Fallen Giant Pfizer (NYSE:PFE | PFE Price Prediction) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted…
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF Energy, Phillips 66, United States Steel and Valero…
Wednesday’s top analyst upgrades and downgrades included Adobe, Akamai Technologies, BridgeBio Pharma, Ciena, Eqonex, Hilton Worldwide, Paysafe, Riot Blockchain, Shopify, Tesla and Williams-Sonoma.
